ClinicalTrials.gg
SuspendedNCT05756556Updated Feb 1, 2024

T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma

A Phase 2 interventional study of T3011 + Cobimetinib in Melanoma and Malignant Melanoma, sponsored by ImmVira Pharma Co. Ltd. Suspended at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-01.

Sponsored by ImmVira Pharma Co. Ltd · Phase 2, Interventional, and Treatment

How we know · 6 judgments

Why this study was suspended
Change in drug development and lifecycle management and decide to suspend this study

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
68
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 27 studies testing cobimetinib in Melanoma — 3 open to participants now, 6 under way, 1 of them phase 3. cobimetinib · Melanoma.

Planned enrollment
11th of 27
68 · median 45
Started
2024
the only one that year
Phase 2
18 of 27
2 open now
Registered
25th of 27
by date

Among the 27 studies testing cobimetinib in Melanoma, this one is the 11th largest by planned enrollment, is the only one that started in 2024, is one of 18 in phase 2, and was the 25th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.

Browse Melanoma studies →

Open to participants now

3 of the 27 studies testing cobimetinib in Melanoma are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About cobimetinib

cobimetinib: first FDA approval 2015 (COTELLIC), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing cobimetinib in Melanoma, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of T3011 in combination with Cobimetinib in patients with advanced melanoma.

Read the detailed description

This is a phase 2a, open-label study of T3011 given via intratumoral (IT) injection in combination with Cobimetinib given via oral administration in patients with advanced melanoma. This study is planned to enroll approximately 62\~68 patients with BRAF V600E/V600K mutation-positive or RAS mutation-positive, which will be conducted in 2 parts (part 1 and part 2).

03

Conditions studied

  • Melanoma
  • Malignant Melanoma

Browse trials for

Keywords

  • intratumoral (IT) injection
  • Cobimetinib
  • advanced melanoma
  • RAS mutation-positive
  • BRAF V600E/V600K mutation-positive
  • stage IIIB to IV advanced malignant melanoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All patients must meet the following criteria for inclusion:

  1. Patient has provided prior to initiation of any study-specific activities/procedures.
  2. Male or female age ≥ 18 years at the time of informed consent.
  3. Willingness to provide pre-and post-treatment fresh tumor specimens as specified in the Schedule of Study Procedures and Assessments (Table 1).
  4. confirmed diagnosis of malignant melanoma (except for uveal melanoma).
  5. Patient with stage IIIB to IV advanced malignant melanoma (as defined by American Joint Committee on Cancer [AJCC] staging manual version 8.0) that is not surgically resectable, failed for standard of care (SOC) therapy or in the opinion of the investigator not suitable for SOC therapy. SOC may include, but not be limited to chemotherapy, targeted therapy or immunotherapy.
  6. BRAF V600E/V600K mutation-positive (applied to part 1 and part 2 cohort 1) or RAS mutation-positive (applied to part 1 and part 2 cohort 2). BRAF V600E/V600K and RAS mutation status result from diagnosis of tumor histopathology should be provided during Screening. If the patient is unable to provide, testing will be required during the Screening period in local laboratory.
  7. defined as one or both of the following:

(1) At least 1 melanoma lesion that can be accurately and serially measured in at least 2 dimensions sand for which the longest diameter is ≥ 10 mm and with perpendicular diameter ≥ 5 mm as measured by contrast-enhanced or spiral CT scan for visceral or nodal/soft tissue disease. Lymph nodes must measure > 15 mm in their short axis to be considered measurable by CT scan.

(2) At least 1 superficial cutaneous or subcutaneous melanoma lesion that can be accurately and serially measured in at least 2 dimensions and for which the short axis is ≥ 5 mm as measured by calipers.

(3) Previously irradiated lesions can be considered as measurable disease only if progressive disease has been unequivocally documented at that lesion since radiation.

  1. Injectable disease (i.e., suitable for direct injection or through the use of ultrasound [US] or CT guidance) defined as follows:
  1. At least 1 injectable melanoma lesion ≥ 5 mm in longest diameter, or in the opinion of the investigator the lesion can be injected.
  1. (ECOG) performance status 0-1.
  1. ≥ 12 weeks.
  1. Adequate bone marrow function defined by of ≥ 1.5 × 109/L, count of ≥ 100 × 109/L, and (Hb) of ≥ 8.5 g/dL.
  1. Adequate hepatic function defined as /ALT ≤ 3 × and total ≤ 1.5 × ULN (except patients with Gilbert's Syndrome, wherein total bilirubin \< 3.0 mg/dL is acceptable; patients with hepatic : AST and/or ALT ≥ 5 × ULN is acceptable; patients with hepatic or bone metastases: ALP ≥ 5 × ULN is acceptable).
  1. Adequate renal function defined as > 50 mL/min as determined by the Cockcroft-Gault equation.
  1. Adequate coagulation function defined as international normalization ratio ()/prothrombin time (PT) ≤ 1.5 × ULN, and partial thromboplastin time (PTT)/ activated PTT (aPTT) ≤ 1.5 × ULN, unless the patient is receiving anticoagulant therapy, in which case PT and PTT/aPTT must be within therapeutic range of intended use of anticoagulants.
  1. Resolution of all prior anti-tumor therapy toxicities (except for alopecia) to ≤ version 5.0 Grade 1.

Note: patients with immune-mediated endocrinopathies on replacement therapy are eligible. Patients with endocrine-related AE who can recover to ≤ NCI CTCAE version 5.0 Grade 1 after hormone replacement therapy, in the judgment of the investigator, have no impact on the safety and efficacy of this study can also be enrolled. Patients with toxicities attributed to the prior anti-tumor therapy and not expected to resolve, such as neuropathy or ototoxicity after platinum-based therapy, are permitted to enroll. Patients with other toxicities > NCI CTCAE version 5.0 Grade 1 may be enrolled with approval from the sponsor.

  1. Female patients must be surgically sterile (or have a monogamous partner who is surgically sterile), or be at least 2 years , or commit to using 2 acceptable forms of (defined as the use of an intrauterine device, a barrier method with spermicide, condoms, any form of hormonal contraceptives, or abstinence) for the duration of the study and for 6 months following the last dose of study treatment. Male patients must be sterile (biologically or surgically) or commit to the use of a reliable method of birth control (condoms with spermicide) for the duration of the study and for 6 months following the last dose of study treatment.
  1. Women of (WCBP) must have a negative serum pregnancy test at Screening within 14 days before the first dose of study treatment on W1D1 and a negative urine pregnancy test pre-dose on W1D1 (assessment not required at W1D1 if completed within the previous 7 days of W1D1).

Note: A woman is considered to be of childbearing potential if she is postmenarchal, has not reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause), and is not permanently infertile due to surgery (i.e., removal of ovaries, fallopian tubes, and/or uterus) or another cause as determined by the investigator (e.g., Müllerian agenesis).

Exclusion criteria

Exclusion Criteria

Patients are to be excluded from the study if they meet any of the following criteria:

  1. Prior treatment with other Oncolytic virus (OV) (including but not be limited to T-VEC), tumor vaccines, cellular therapy or gene therapy.
  2. Prior local anti-tumor therapy \< 21 days prior to the first dose of study treatment; prior systemic targeted therapy (including but not be limited to MEK inhibitors) \< 21 days or last dose of therapy with MEK inhibitors \< 5 times the half-life prior to first dose of study treatment; prior other anti-tumor therapy (including but not be limited to /programmed cell death ligand 1[PD-L1]) \< 21 days prior to the first dose of study treatment, prior major surgery \< 21 days prior to the first dose of study treatment.
  3. Prior treatment with anti-PD-(L)1 monoclonal Ab in combination with IL-12.
  4. Previous intolerance to anti-PD-(L)1 monoclonal Ab or previous history of immunotherapy induced ≥ version 5.0 Grade 3 non-infectious pneumonitis/interstitial lung disease.
  5. The following foods/supplements are used within 7 days before the study treatment or the following foods/supplements are planned to be used during the study treatment:

(1) St. John's wort or hyperforin (potent cytochrome P450 enzyme inducer).

(2) Grapefruit juice (potent cytochrome P450 CYP3A4 enzyme inhibitor).

  1. nausea and vomiting, chronic gastrointestinal diseases or previous significant bowel resection that would interfere with absorption of study drugs, inability or unwillingness to swallow the formulated product.
  1. A history of to the brain stem, midbrain, pons/medulla oblongata, or within 10 mm of optic nerve organs (optic nerve and optic chiasma); Or a history of .
  1. Patients with rapidly disease progression, defined as patients who cannot tolerate interruption of systemic anti-tumor therapy for at least 8 weeks, according to the investigator's judgment.
  1. Primary or acquired immunodeficient status (leukemia, lymphoma, [HIV]/acquired immunodeficiency syndrome [AIDS]).
  1. History or evidence of active disease that requires systemic treatment (i.e., with use of disease modifying agents, or drugs) within 4 weeks prior to first dose of study treatment. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  1. History or evidence of active primary immunodeficiency. 12. Current or prior use of immunosuppressive medication within 14 days before the first dose of study drug. The following are exceptions to this criterion:
  1. Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra-articular injection).
  2. Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent.
  3. Steroids as premedication for reactions (e.g., CT scan premedication).
  1. Requires continued concurrent systemic therapy with any drug active against herpes simplex virus (HSV) (acyclovir, valaciclovir, penciclovir, famciclovir, ganciclovir, foscarnet, cidofovir). Topical use of drugs against HSV are allowed.
  1. Live, attenuated vaccines within 4 weeks prior to initiation of study treatment (patients vaccinated with inactivated vaccines can be enrolled).
  1. Active infection requiring systemic treatment. 16. Hepatic diseases known to be include alcoholism, cirrhosis, fatty hepatic disease, and other hereditary hepatic diseases, or positive serological test of virus (HBV) or virus (HCV) at Screening.
  1. Patients who test positive for anti-hepatitis C Ab (anti-HCV) but negative for HCV ribonucleic acid (RNA) are considered eligible to participate in the study.
  2. Patients with infection of hepatitis B (positive hepatitis B surface antigen [HBsAg] result) will be excluded. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core Ab [HBcAb] and absence of HBsAg) are eligible.
  1. Female patient is pregnant or breast-feeding, or planning to become pregnant during study treatment and through 6 months after the last dose of study treatment.
  1. History of or evidence of retinal pathology on ophthalmologic examination that is considered a risk factor for neurosensory retinal detachment, central serous chorioretinopathy, retinal vein occlusion (RVO), or neovascular macular degeneration. Patients will be excluded from study participation if they currently are known to have any of the following risk factors for RVO:
  1. History of serous retinopathy;
  2. History of retinal vein occlusion;
  3. Evidence of ongoing serous retinopathy or RVO at baseline.
  1. Patients with active central nervous system (CNS) lesions (i.e., those with radiographically unstable, symptomatic lesions, including but not limited to carcinomatous meningitis) and history of intracranial hemorrhage are excluded. However, patients are eligible if:
  1. Patients with all known CNS lesions have been treated with stereotactic therapy or surgery, whose disease is stable without using corticosteroids; AND
  2. There has been no evidence of clinical and radiographic disease progression in the CNS for ≥ 3 weeks after radiotherapy or surgery.
  1. History of another primary malignant tumor, except the following: 1) the patient has undergone potentially curative therapy with no evidence of that disease and recurrence for 3 years prior to the first dose of study treatment; 2) Adequately treated non-melanoma skin cancer or lentigo with no evidence of ; 3) Adequately treated carcinoma in situ without evidence of disease.
  1. Patients with moderate to large amount of pleural effusion, ascites or pericardial effusion who need drug or medical intervention. Patient may be eligible to participate following discussion with investigator and approval from the sponsor.
  1. Unexplained > 38.5℃ fever (If the fever is caused by the tumor according to the investigator's judgment, the patient can be enrolled) occurs during the Screening period or on the day of administration, which in the judgment of investigator, would interfere with patient participation in the study or evaluation of patient's efficacy.
  1. History of seizure disorders within 6 months prior to Screening. 24. Active oral or skin herpes lesion at Screening. 25. Plan to receive any other anti-tumor therapy (including herbal therapy that has anti-tumor effects) during treatment with study drug.
  1. History of congestive heart failure (> Class II), active coronary artery disease, unevaluated new onset angina within 3 months or unstable angina (angina symptoms at rest), below institutional lower limit of normal or below 50%, whichever is lower, poorly controlled hypertension, defined as sustained, uncontrolled, nonepisodic baseline hypertension consistently above 159/99 mmHg despite optimal medical management, or clinically significant cardiac arrhythmias.
  1. Uncontrolled diabetes or symptomatic hyperglycemia. 28. History of allergic reactions attributed to compounds of similar biological composition to HSV-1, IL-12, or anti-PD-1 monoclonal Ab or their .
  1. History of psychiatric disorders that would interfere with cooperation with the requirements of the trial or is still requiring for medication control.
  1. History of substance abuse (including alcohol) within 6 months prior to signing .
  1. Other systemic conditions or organ abnormalities that, in the opinion of the investigator, may interfere with the conduct and/or interpretation of the current study.
Terms in these criteria, in plain language(35)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
68 participants (estimated)

Study arms

  • Experimental
    Phase 2a

    T3011 given via intratumoral (IT) injection in combination with Cobimetinib via oral administration in patients with advanced melanoma.

    Combination Product: T3011 + Cobimetinib

Interventions

06

What researchers measure

Primary outcomes

  1. ORR

    defined as the proportion of patients with a CR or PR on two consecutive occasions ≥ 4 weeks apart, as determined by the investigator according to RECIST version 1.1

    Time frame: up to 5 years after the first dose of the last patient, depending on the actual situation.

  2. Characterize the safety and tolerability of T3011 in combination with Cobimetinib.

    Incidence and severity of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), dose-limiting toxicities (DLTs) (part 1 only), adverse event of special interest (AESIs), abnormal clinically significant vital signs, physical examination, and laboratory tests, with severity determined according to national cancer institute (NCI) common terminology criteria for adverse events (CTCAE) version 5.0.

    Time frame: up to 5 years after the first dose of the last patient, depending on the actual situation.

Secondary outcomes

  1. Overall Survival (OS)

    defined as the time from initiation of study treatment to death from any cause

    Time frame: up to 5 years after the first dose of the last patient, depending on the actual situation.

  2. Progression-free survival (PFS)

    defined as the time from initiation of study treatment to the first occurrence of disease progression or death from any cause (whichever occurs first), as determined by the investigator according to RECIST version 1.1

    Time frame: up to 5 years after the first dose of the last patient, depending on the actual situation.

  3. Disease control rate (DCR)

    defined as the proportion of patients who have a best overall response of CR or PR or SD, as determined by the investigator according to RECIST version 1.1.

    Time frame: up to 5 years after the first dose of the last patient, depending on the actual situation.

  4. Duration of response (DOR)

    defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause (whichever occurs first), as determined by the investigator according to RECIST version 1.1.

    Time frame: up to 5 years after the first dose of the last patient, depending on the actual situation.

  5. European Organization for Research and Treatment of Cancer Questionnaire Core 30 (EORTC QLQ-C30)

    Change from baseline in the European Organization for Research and Treatment of Cancer Questionnaire Core 30 (EORTC QLQ-C30) (version 3.0) at subsequent visits protocol required.

    Time frame: up to 5 years after the first dose of the last patient, depending on the actual situation.

07

Study locations

1 site
  • Gabrail Cancer and Research Center
    Canton, Ohio 44718, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2024; primary completion for Dec 2026, 30 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2022
First posted
Mar 6, 2023
StartEst.
Jun 30, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jan 1, 2027
Last update
Feb 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05756556
Lead sponsor
ImmVira Pharma Co. Ltd
Responsible party
Sponsor
First posted
Mar 6, 2023
Start date
Jun 30, 2024 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Feb 1, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Oncolytic HSV-1 Expressing IL-12 and Anti-PD-1 Antibody T3011 · Cobimetinib

Start the discussion